Canada Sleep Apnea Devices Market Research Report 2024: Opportunities and Forecasts to 2029 Featuring Braebon Medical, VitalAire, FPM Solutions, So...
Dublin, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The "Canada Sleep Apnea Devices Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ResearchAndMarkets.com's off...
Here's Why ResMed (RMD) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD)
ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ResMed's Stock Rises on Q1 Earnings and Revenue Beat, Margins Expand
RMD's stellar first-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.
ResMed Inc. (RMD) Q1 2025 Earnings Call Transcript
ResMed Inc. (NYSE:RMD ) Q1 2025 Earnings Conference Call October 24, 2024 4:30 PM ET Company Participants Amy Wakeham - Chief Investor Relations Officer Michael Farrell - Chairman and Chief Executi...
ResMed (RMD) Surpasses Q1 Earnings and Revenue Estimates
ResMed (RMD) came out with quarterly earnings of $2.20 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.64 per share a year ago.
ResMed (RMD) is an Incredible Growth Stock: 3 Reasons Why
ResMed (RMD) could produce exceptional returns because of its solid growth attributes.
Is ResMed Stock a Smart Addition to Your Portfolio Right Now?
RMD's robust mask business and efforts to boost its SaaS business are encouraging.
ResMed: Growing Returns With Continuous Acquisitions Led To A Margin Of Safety
ResMed achieved double-digit revenue and profit growth over the past 9 years, driven by continuous acquisitions and improving operating efficiencies. ResMed's capital efficiencies showed mixed resu...
Why ResMed Stock Tumbled by 5% Today
An analyst downgraded his recommendation on the medical device specialist. He now feels investors should avoid it.
S&P 500 Gains and Losses Today: Medical Device Makers ResMed, Insulet Lead Index
Major U.S. equities indexes ticked higher ahead of a potentially consequential earnings report from semiconductor giant Nvidia (NVDA) as well as key inflation and economic data set for release late...
ResMed Shares Breathing Life into Big Money Portfolios
Leading respiratory care device maker ResMed Inc. (RMD) is a profit producing machine.
ResMed's (RMD) Q4 Earnings Surpass Estimates, Margins Expand
ResMed (RMD) delivers solid performance across all regions and business segments in the fourth quarter of fiscal 2024.
Lost Money on ResMed Inc. (RMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federa...
ResMed (RMD) Beats Q4 Earnings and Revenue Estimates
ResMed (RMD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.60 per share a year ago.
Related Companies